Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

Ingrid A. Mayer, MD
Published: Wednesday, Feb 03, 2016



Ingrid A. Mayer, MD, co-leader and clinical director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, associate professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

In the early setting, targeted therapies are being incorporated in both the adjuvant and neoadjuvant settings, says Mayer. There are several trials ongoing and being planned utilizing CDK4/6 inhibitors, as well as everolimus. If these trials end up showing a survival advantage, it would revolutionize the way patients with ER-positive breast cancer are treated, she says.

In the metastatic setting, there are also numerous targeted therapies being investigated including CDK4/6 inhibitors, PI3-kinase inhibitors, histone deacetylase inhibitors, EGFR inhibitors, and more. Patient selection is going to be one of the biggest challenges, says Mayer. Instead of large trials, studies may need to be smaller and more specific going forward.



Ingrid A. Mayer, MD, co-leader and clinical director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, associate professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

In the early setting, targeted therapies are being incorporated in both the adjuvant and neoadjuvant settings, says Mayer. There are several trials ongoing and being planned utilizing CDK4/6 inhibitors, as well as everolimus. If these trials end up showing a survival advantage, it would revolutionize the way patients with ER-positive breast cancer are treated, she says.

In the metastatic setting, there are also numerous targeted therapies being investigated including CDK4/6 inhibitors, PI3-kinase inhibitors, histone deacetylase inhibitors, EGFR inhibitors, and more. Patient selection is going to be one of the biggest challenges, says Mayer. Instead of large trials, studies may need to be smaller and more specific going forward.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x